H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent

Rubén W. Carón, Adly Yacoub, Xiaoyu Zhu, Clint Mitchell, Song Iy Han, Takehiko Sasazuki, Senji Shirasawa, Michael P. Hagan, Steven Grant, Paul Dent

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The abilities of mutated active K-RAS and H-RAS proteins, in an isogenic human carcinoma cell system, to modulate the activity of signaling pathways following exposure to ionizing radiation is unknown. Loss of K-RAS D13 expression in HCT116 colorectal carcinoma cells blunted basal extracellular signal-regulated kinase 1/2 (ERK1/2), AKT, and c-Jun NH2-terminal kinase 1/2 activity. Deletion of the allele to express K-RAS D13 also enhanced expression of ERBB1, ERBB3, and heregulin but nearly abolished radiation-induced activation of all signaling pathways. Expression of H-RAS V12 in HCT116 cells lacking an activated RAS molecule (H-RAS V12 cells) restored basal ERK1/2 and AKT activity to that observed in parental cells but did not restore or alter basal c-jun NH2-kinase 1/2 activity. In parental cells, radiation caused stronger ERK1/2 pathway activation compared with that of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which correlated with constitutive translocation of Raf-1 into the plasma membrane of parental cells. Inhibition of mitogen-activated protein kinase/ERK1/2, but not PI3K, radiosensitized parental cells. In H-RAS V12 cells, radiation caused stronger PI3K/AKT pathway activation compared with that of the ERK1/2 pathway, which correlated with H-RAS V12-dependent translocation of PI3K into the plasma membrane. Inhibition of PI3K, but not mitogen-activated protein kinase/ERK1/2, radiosensitized H-RAS V12 cells. Radiation-induced activation of the PI3K/AKT pathway in H-RAS V12 cells 2 to 24 hours after exposure was dependent on heregulin-stimulated ERBB3 association with membrane-localized PI3K. Neutralization of heregulin function abolished radiation-induced AKT activation and reverted the radiosensitivity of H-RAS V12 cells to those levels found in cells lacking expression of any active RAS protein. These findings show that H-RAS V12 and K-RAS D13 differentially regulate radiation-induced signaling pathway function. In HCT116 cells expressing H-RAS V12, PI3K-dependent radioresistance is mediated by both H-RAS-dependent translocation of PI3K into the plasma membrane and heregulin-induced activation of membrane-localized PI3K via ERBB3.

Original languageEnglish
Pages (from-to)243-255
Number of pages13
JournalMolecular Cancer Therapeutics
Volume4
Issue number2
Publication statusPublished - Feb 1 2005
Externally publishedYes

Fingerprint

Neuregulin-1
Phosphatidylinositol 3-Kinase
Colon
Carcinoma
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Radiation
HCT116 Cells
Cell Membrane
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase 8
Membranes
JNK Mitogen-Activated Protein Kinases
Radiation Tolerance
Ionizing Radiation
Colorectal Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Carón, R. W., Yacoub, A., Zhu, X., Mitchell, C., Han, S. I., Sasazuki, T., ... Dent, P. (2005). H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Molecular Cancer Therapeutics, 4(2), 243-255.

H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. / Carón, Rubén W.; Yacoub, Adly; Zhu, Xiaoyu; Mitchell, Clint; Han, Song Iy; Sasazuki, Takehiko; Shirasawa, Senji; Hagan, Michael P.; Grant, Steven; Dent, Paul.

In: Molecular Cancer Therapeutics, Vol. 4, No. 2, 01.02.2005, p. 243-255.

Research output: Contribution to journalArticle

Carón, RW, Yacoub, A, Zhu, X, Mitchell, C, Han, SI, Sasazuki, T, Shirasawa, S, Hagan, MP, Grant, S & Dent, P 2005, 'H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent', Molecular Cancer Therapeutics, vol. 4, no. 2, pp. 243-255.
Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T et al. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Molecular Cancer Therapeutics. 2005 Feb 1;4(2):243-255.
Carón, Rubén W. ; Yacoub, Adly ; Zhu, Xiaoyu ; Mitchell, Clint ; Han, Song Iy ; Sasazuki, Takehiko ; Shirasawa, Senji ; Hagan, Michael P. ; Grant, Steven ; Dent, Paul. / H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 2. pp. 243-255.
@article{32fae9d88b2d437b9840f83fd7f20a94,
title = "H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent",
abstract = "The abilities of mutated active K-RAS and H-RAS proteins, in an isogenic human carcinoma cell system, to modulate the activity of signaling pathways following exposure to ionizing radiation is unknown. Loss of K-RAS D13 expression in HCT116 colorectal carcinoma cells blunted basal extracellular signal-regulated kinase 1/2 (ERK1/2), AKT, and c-Jun NH2-terminal kinase 1/2 activity. Deletion of the allele to express K-RAS D13 also enhanced expression of ERBB1, ERBB3, and heregulin but nearly abolished radiation-induced activation of all signaling pathways. Expression of H-RAS V12 in HCT116 cells lacking an activated RAS molecule (H-RAS V12 cells) restored basal ERK1/2 and AKT activity to that observed in parental cells but did not restore or alter basal c-jun NH2-kinase 1/2 activity. In parental cells, radiation caused stronger ERK1/2 pathway activation compared with that of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which correlated with constitutive translocation of Raf-1 into the plasma membrane of parental cells. Inhibition of mitogen-activated protein kinase/ERK1/2, but not PI3K, radiosensitized parental cells. In H-RAS V12 cells, radiation caused stronger PI3K/AKT pathway activation compared with that of the ERK1/2 pathway, which correlated with H-RAS V12-dependent translocation of PI3K into the plasma membrane. Inhibition of PI3K, but not mitogen-activated protein kinase/ERK1/2, radiosensitized H-RAS V12 cells. Radiation-induced activation of the PI3K/AKT pathway in H-RAS V12 cells 2 to 24 hours after exposure was dependent on heregulin-stimulated ERBB3 association with membrane-localized PI3K. Neutralization of heregulin function abolished radiation-induced AKT activation and reverted the radiosensitivity of H-RAS V12 cells to those levels found in cells lacking expression of any active RAS protein. These findings show that H-RAS V12 and K-RAS D13 differentially regulate radiation-induced signaling pathway function. In HCT116 cells expressing H-RAS V12, PI3K-dependent radioresistance is mediated by both H-RAS-dependent translocation of PI3K into the plasma membrane and heregulin-induced activation of membrane-localized PI3K via ERBB3.",
author = "Car{\'o}n, {Rub{\'e}n W.} and Adly Yacoub and Xiaoyu Zhu and Clint Mitchell and Han, {Song Iy} and Takehiko Sasazuki and Senji Shirasawa and Hagan, {Michael P.} and Steven Grant and Paul Dent",
year = "2005",
month = "2",
day = "1",
language = "English",
volume = "4",
pages = "243--255",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent

AU - Carón, Rubén W.

AU - Yacoub, Adly

AU - Zhu, Xiaoyu

AU - Mitchell, Clint

AU - Han, Song Iy

AU - Sasazuki, Takehiko

AU - Shirasawa, Senji

AU - Hagan, Michael P.

AU - Grant, Steven

AU - Dent, Paul

PY - 2005/2/1

Y1 - 2005/2/1

N2 - The abilities of mutated active K-RAS and H-RAS proteins, in an isogenic human carcinoma cell system, to modulate the activity of signaling pathways following exposure to ionizing radiation is unknown. Loss of K-RAS D13 expression in HCT116 colorectal carcinoma cells blunted basal extracellular signal-regulated kinase 1/2 (ERK1/2), AKT, and c-Jun NH2-terminal kinase 1/2 activity. Deletion of the allele to express K-RAS D13 also enhanced expression of ERBB1, ERBB3, and heregulin but nearly abolished radiation-induced activation of all signaling pathways. Expression of H-RAS V12 in HCT116 cells lacking an activated RAS molecule (H-RAS V12 cells) restored basal ERK1/2 and AKT activity to that observed in parental cells but did not restore or alter basal c-jun NH2-kinase 1/2 activity. In parental cells, radiation caused stronger ERK1/2 pathway activation compared with that of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which correlated with constitutive translocation of Raf-1 into the plasma membrane of parental cells. Inhibition of mitogen-activated protein kinase/ERK1/2, but not PI3K, radiosensitized parental cells. In H-RAS V12 cells, radiation caused stronger PI3K/AKT pathway activation compared with that of the ERK1/2 pathway, which correlated with H-RAS V12-dependent translocation of PI3K into the plasma membrane. Inhibition of PI3K, but not mitogen-activated protein kinase/ERK1/2, radiosensitized H-RAS V12 cells. Radiation-induced activation of the PI3K/AKT pathway in H-RAS V12 cells 2 to 24 hours after exposure was dependent on heregulin-stimulated ERBB3 association with membrane-localized PI3K. Neutralization of heregulin function abolished radiation-induced AKT activation and reverted the radiosensitivity of H-RAS V12 cells to those levels found in cells lacking expression of any active RAS protein. These findings show that H-RAS V12 and K-RAS D13 differentially regulate radiation-induced signaling pathway function. In HCT116 cells expressing H-RAS V12, PI3K-dependent radioresistance is mediated by both H-RAS-dependent translocation of PI3K into the plasma membrane and heregulin-induced activation of membrane-localized PI3K via ERBB3.

AB - The abilities of mutated active K-RAS and H-RAS proteins, in an isogenic human carcinoma cell system, to modulate the activity of signaling pathways following exposure to ionizing radiation is unknown. Loss of K-RAS D13 expression in HCT116 colorectal carcinoma cells blunted basal extracellular signal-regulated kinase 1/2 (ERK1/2), AKT, and c-Jun NH2-terminal kinase 1/2 activity. Deletion of the allele to express K-RAS D13 also enhanced expression of ERBB1, ERBB3, and heregulin but nearly abolished radiation-induced activation of all signaling pathways. Expression of H-RAS V12 in HCT116 cells lacking an activated RAS molecule (H-RAS V12 cells) restored basal ERK1/2 and AKT activity to that observed in parental cells but did not restore or alter basal c-jun NH2-kinase 1/2 activity. In parental cells, radiation caused stronger ERK1/2 pathway activation compared with that of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which correlated with constitutive translocation of Raf-1 into the plasma membrane of parental cells. Inhibition of mitogen-activated protein kinase/ERK1/2, but not PI3K, radiosensitized parental cells. In H-RAS V12 cells, radiation caused stronger PI3K/AKT pathway activation compared with that of the ERK1/2 pathway, which correlated with H-RAS V12-dependent translocation of PI3K into the plasma membrane. Inhibition of PI3K, but not mitogen-activated protein kinase/ERK1/2, radiosensitized H-RAS V12 cells. Radiation-induced activation of the PI3K/AKT pathway in H-RAS V12 cells 2 to 24 hours after exposure was dependent on heregulin-stimulated ERBB3 association with membrane-localized PI3K. Neutralization of heregulin function abolished radiation-induced AKT activation and reverted the radiosensitivity of H-RAS V12 cells to those levels found in cells lacking expression of any active RAS protein. These findings show that H-RAS V12 and K-RAS D13 differentially regulate radiation-induced signaling pathway function. In HCT116 cells expressing H-RAS V12, PI3K-dependent radioresistance is mediated by both H-RAS-dependent translocation of PI3K into the plasma membrane and heregulin-induced activation of membrane-localized PI3K via ERBB3.

UR - http://www.scopus.com/inward/record.url?scp=20044363654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044363654&partnerID=8YFLogxK

M3 - Article

C2 - 15713896

AN - SCOPUS:20044363654

VL - 4

SP - 243

EP - 255

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -